tiprankstipranks
Advertisement
Advertisement

NBIX Stock Latest News

Neurocrine initiates Phase 2 study of crinecerfont
The FlyNeurocrine initiates Phase 2 study of crinecerfont
16h ago
NBIX
Neurocrine price target raised to $208 from $182 at UBS
PremiumThe Fly
Neurocrine price target raised to $208 from $182 at UBS
2d ago
NBIX
Neurocrine’s Valbenazine Huntington Study Completion Signals Next Phase for NBIX Investors
PremiumCompany Announcements
Neurocrine’s Valbenazine Huntington Study Completion Signals Next Phase for NBIX Investors
15d ago
NBIX
Neurocrine: Pipeline De-Risking With Positive Crenessity and Vykat XR Data; Buy Rating Reiterated, $246 Price Target Unchanged
PremiumRatings
Neurocrine: Pipeline De-Risking With Positive Crenessity and Vykat XR Data; Buy Rating Reiterated, $246 Price Target Unchanged
16d ago
NBIX
Soleno Therapeutics presents new VYKAT XR data at ENDO 2026
PremiumThe Fly
Soleno Therapeutics presents new VYKAT XR data at ENDO 2026
17d ago
NBIX
Neurocrine presents first retrospective case series of Crenessity
PremiumThe FlyNeurocrine presents first retrospective case series of Crenessity
17d ago
NBIX
Neurocrine presents two-year Crenessity data
Premium
The Fly
Neurocrine presents two-year Crenessity data
17d ago
NBIX
Neurocrine reports new post-hoc data from KINECT 4 trial
Premium
The Fly
Neurocrine reports new post-hoc data from KINECT 4 trial
24d ago
NBIX
Neurocrine presents new data showing Improvements with INGREZZA
PremiumThe Fly
Neurocrine presents new data showing Improvements with INGREZZA
24d ago
NBIX
Myles Minter Reiterates Buy on Neurocrine, Citing Diversified Commercial Franchise, Robust Ingrezza Growth, and Catalyst-Rich Late-Stage Pipeline
PremiumRatings
Myles Minter Reiterates Buy on Neurocrine, Citing Diversified Commercial Franchise, Robust Ingrezza Growth, and Catalyst-Rich Late-Stage Pipeline
30d ago
NBIX
Meta Platforms upgraded, Okta downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Meta Platforms upgraded, Okta downgraded: Wall Street’s top analyst calls
30d ago
KNX
SHW
Neurocrine reinstated with a Buy at Goldman Sachs
PremiumThe Fly
Neurocrine reinstated with a Buy at Goldman Sachs
1M ago
NBIX
Neurocrine price target raised to $183 from $180 at RBC Capital
PremiumThe FlyNeurocrine price target raised to $183 from $180 at RBC Capital
1M ago
NBIX
Neurocrine Shareholders Reelect Directors and Approve Governance Measures
Premium
Company Announcements
Neurocrine Shareholders Reelect Directors and Approve Governance Measures
1M ago
8K
NBIX
Neurocrine initiated with Outperform at Bernstein on long runway of key drugs
Premium
The Fly
Neurocrine initiated with Outperform at Bernstein on long runway of key drugs
1M ago
NBIX
Neurocrine initiated with an Outperform at Bernstein
PremiumThe Fly
Neurocrine initiated with an Outperform at Bernstein
1M ago
NBIX
Neurocrine’s New Tardive Dyskinesia Trial Adds Fresh Optionality for NBIX Investors
PremiumCompany Announcements
Neurocrine’s New Tardive Dyskinesia Trial Adds Fresh Optionality for NBIX Investors
1M ago
NBIX
Neurocrine announces new data from a clinician survey in Ingrezza
PremiumThe Fly
Neurocrine announces new data from a clinician survey in Ingrezza
1M ago
NBIX
Neurocrine Closes Soleno Deal, Expands Rare Disease Portfolio
PremiumCompany Announcements
Neurocrine Closes Soleno Deal, Expands Rare Disease Portfolio
1M ago
8K
NBIX
Neurocrine completes acquisition of Soleno Therapeutics
PremiumThe FlyNeurocrine completes acquisition of Soleno Therapeutics
1M ago
NBIX
SLNO
Aardvark Therapeutics downgraded to Underperform from Buy at BofA
Premium
The Fly
Aardvark Therapeutics downgraded to Underperform from Buy at BofA
2M ago
AARD
NBIX
Neurocrine price target raised to $185 from $177 at JPMorgan
Premium
The Fly
Neurocrine price target raised to $185 from $177 at JPMorgan
2M ago
NBIX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >